

2026 NBRP DEMO & PITCH DAY


*Science to Impact,
Powered by Innovation and Resources*



JULY 13-14



國家生技研究園區C棟



主辦單位 /



NBRP 國家生技研究園區
國家生技研究園區

BioReC
生物資源研究中心

共同主辦單位 /



生物技術開發中心
Biotechnology Center for Development

從技術到應用

整合多元核心設施與專業服務
支援完成每一階段的生醫研究

Integrated Core Facilities
Accelerating Biomedical Translation



整合核心設施 · 加速生醫轉譯

Integrated Core Facilities • Accelerating Biomedical Translation



精準醫療與基因體平台

Precision Medicine
& Genomics

臨床前驗證與影像平台

Preclinical Validation
& Translational Imaging

前瞻藥物與抗體研發平台

Advanced Drug & Therapeutic
Discovery



前瞻科技 產業落地



研發能量

Research & Development

- 生技藥品
- 基因和細胞製劑
- 新型態鏈結藥物
- 精準小分子
- 核酸藥物
- 抗體藥物複合體



技術服務

Contract Services

- 藥物標的評估
- 藥品篩選及最適化
- 臨床前藥效評估
- 臨床前藥毒理
- AI輔助新藥開發



產業發展

Industry Promotion

- 產業分析
- 專利布局
- 新創加速
- 技術移轉
- 商務談判
- 國際媒合



請掃描QRcode獲得更多生技中心官網及社群專頁詳情

國家生技研究園區

台北市南港區研究院路一段130巷107號E棟

汐止園區

新北市汐止區康寧街169巷101號

南港軟體園區

台北市南港區園區街3號17樓



02-7700-3800



www.dcb.org.tw

台灣臨床前試驗聯盟

Taiwan Contract Research One-Stop Service, T.CROSS

Joint Laboratories' Core Capabilities in Drug Development



工業技術研究院
Industrial Technology
Research Institute



財團法人生物技術開發中心
Development Center for Biotechnology



國家衛生研究院
National Health Research Institutes

早期開發

先導化合物篩選與優化

- 候選藥物目標產品特徵(Target Profile)建立
- 化合物小規模生產與化學性質研究
- 體內與體外藥效學研究
- 早期藥物動力學與物種選擇研究
- 早期毒理與安全性評估

ADMET

藥物代謝與藥動研究

- 核心 ADMET 與藥物動力學研究
- Non-GLP 毒理與毒代動力學試驗
- CMC生產時程與規劃確認
- 製劑與生物分析方法建立

合規服務

臨床前安全性與IND準備

- 製劑與生物分析方法確效
- 基因毒性試驗
- 安全藥理試驗
- 重複劑量毒性與毒代動力學試驗
- 臨床一期試驗之初步規劃



<https://t.cross.org.tw/index.html>



info@t.cross.org.tw



Journal of Food and Drug Analysis



Call for Papers

Aim and Scope

The *Journal of Food and Drug Analysis (JFDA)* is the official peer-reviewed publication of the Food and Drug Administration, Taiwan (TFDA). It is published quarterly by Elsevier in March, June, September and December. The Journal aims to publish original research and review papers on the analysis of food, medicine, traditional Chinese medicine, toxicology, medical devices, drugs, and cosmetics as well as related disciplines that are of topical interest to the public health profession.

Indexed in: Scopus, Embase, PubMed, PubMed Central

Abstracting: Biochemistry & Biophysics Citation Index MEDLINE®, EMBASE, FSTA (Food Science and Technology Abstracts), Research Alert, BIOSIS Previews, ScienceDirect, Chemical Abstracts Service, Scopus, Science Citation Index Expanded, Abstracts of Chinese Medicines


Submission

Authors are welcome to submit reviews, original articles, case reports, and research notes for consideration. Please submit your manuscripts online at:

www.jfda-online.com/journal



Free for publication



Frequency: Quarterly

ISSN: 1021-9498

Specialty: food, medicine, traditional Chinese medicine, toxicology, medical devices, drugs, and cosmetics



Website

Free full-text articles available online at:

www.jfda-online.com/journal

▲藥品▲醫療器材▲製造技術

2026 國家藥物科技 研究發展獎



藥物領航

躍升國際

徵件延長報名至

07.31 (Fri.)

▲徵件3類別

藥品 醫療器材 製造技術

▲申請資格

凡國內之藥物製造廠、醫療器材商及從事藥物研發或醫療器材
創新科技研究發展之自然人、法人、學校、機構或團體皆可申請。

▲收件地址

231新北市新店區北新路三段205-2號8樓
林小姐 02-8913-1111#202
2026國家藥物科技研究發展獎工作小組 收

活動官網



**2026
NPRDA**

National
Pharmaceutical Technology
Research
Development
Award



產業發展署 廣告

Health Industries Services

PwC Bio Team

Our Core Values and Support

As of 2026, PwC Taiwan remains deeply engaged in helping Taiwan's biotechnology and healthcare industries. Our Health Industries Services Group continues to explore pivotal sector topics, regularly updating the Chat of Healthcare podcast and the PwC Bio Insights publications.

Drawing on years of accumulated research data and the expertise of our multidisciplinary team—comprising industry consultants, lawyers, and accountants—we stand ready to serve the biomedical sector. We are dedicated to fulfilling the three core missions of our biomedical division: serving biomedical clients, supporting the industry, and contributing to Taiwan's future.

Current Status and Trends in Precision Care



Current Status and Trends in Precision Medicine



Current Status and Trends in Precision Testing, Prevention, and Diagnosis



"PwC Bio Insights" Publications



PwC connects to a global resource database and publishes industry trend reports on topics such as digital health, precision medicine, CDMO, and other innovative fields within the biotech industry.

Chat of Healthcare podcast



PwC invites industry experts to discuss critical topics and share their experiences and the latest industry trends.

Biotech Startup Classroom



PwC has curated a series of video courses specifically for the needs of biotech start-ups, enabling entrepreneurs to quickly grasp the secrets of rapid growth.

How we can help

- Assurance Services
- Corporate Tax Services
- Individual Tax Services
- Risk Management Services
- Market Entry Services
- Intellectual Property Legal Services
- Shareholder Rights Services
- Advisory and Consulting Services

Subscribe to Us



Discover More





100%



昶安代理品牌齊全



服務 · 熱情 · 暖心



progress happens together
abcam



一級/二級抗體



ELISA kit



生物活性蛋白



細胞功能分析



抗體標定試劑



基因剔除細胞株



客製化產品

BioLegend®

BioLegend's class-leading products and service
now power Revvity's Cell Analysis portfolio.

免疫螢光抗體 多因子分析試 單細胞蛋白組

細胞治療 Cell-Vive™ GMP 試劑



revvity

ELISA . Chemicals . Toxins

Cayman Chemical 致力於生化藥品合成與純化、抗氧化試劑及各種酵素活性分析套組之研發與生產，
且擁有 ISO / IEC 17025:2005 和 ISO Guide 34:2009 雙重認證，為氧化壓力檢測產品的領導先驅。





— 主任的話 —

在全球生醫科技快速迭代的浪潮中，創新是引領產業突破的關鍵。

「2026 NBRP Demo & Pitch Day」首採產業市場與技術轉譯兩面向雙軌並進，匯聚國內外創投、藥廠與產官學研菁英。精準對接前瞻技術與豐厚資源，將臺灣生醫的創新底蘊，轉化為鏈結國際市場的強大動能。

國家生技研究園區作為臺灣生醫發展的核心樞紐，持續深耕完整生醫生態系，致力打通學研轉譯至資源鏈結的最後一哩路。期盼大會成為驅動跨域、跨界合作的引擎，引領臺灣生醫邁向國際戰略新局。

誠摯感謝所有與會貴賓、特邀講者、合作夥伴及技術團隊的鼎力支持，讓我們攜手在變革中掌握先機，共創臺灣生醫深具全球影響力的新紀元。我要特別感謝生物技術開發中心承接園區創服育成中心的委託服務案，並籌辦此次活動。最後，敬祝本次大會圓滿成功！

陳建璋

2026 NBRP DEMO & PITCH DAY

Science to Impact,
Powered by Innovation and Resources



研發資源整合

國家生技研究園區聚集醫療研發之各關鍵步驟，
打造臺灣第一個跨部會生技產業推動研發聚落，
帶動臺灣生技產業蓬勃發展。



BioReC
生醫轉譯研究中心
Biomedical Translation Research Center

中央研究院 生醫轉譯研究中心

推動中研院「深度轉譯」，深厚基礎研究開展為具體應用，並推動創新關鍵技術發展及核心設施服務，以加速研發進程，並與進駐單位共同管理園區內之公共事務及維護生態環境。

提供育成空間，開放國內以生醫研發為主之公司或以本國為研發基地之國際公司申請租用。



DOB 生物技術開發中心
Development Center for Biotechnology

經濟部財團法人 生物技術開發中心

專精新藥臨床前開發與轉譯加值服務，提供案源評估、技術授權、以及新創育成之商品化服務。



衛生福利部 食品藥物管理署

提供醫藥產業輔導、法規諮詢服務，以增進醫藥產品競爭力與生技開發整合。



國科會國家實驗研究院 國家生物模式

提供多元化動物資源及試驗服務。支援生醫產品開發與醫學研究。加速生技產業國際化。



官方網站



f FACEBOOK



YOUTUBE



為配合國家生技產業的發展及國家生技研究園區的成立，中央研究院特別設置生醫轉譯研究中心於 2019 年 9 月進駐園區，負責推動創新生技產業的發展及維護園區生態環境的平衡。「生醫轉譯研究中心」以提供整合式的資源與平台，協助生技新創人才與團隊加速達成其產品化的進程，促進基礎研究成果的活用，並以造福社會與增進國人之健康福祉為最大目標。



核酸醫療專題中心

開發個人化腫瘤新抗原 (neoantigen) mRNA 疫苗
推動中研院轉譯醫學研究。

新興傳染病專題中心

打造以奠基於科學研究並與全球連結的新興傳染病創新研究中心，主動介入傳染病生態、偵測跨宿主風險、發展干預技術，守護臺灣，鏈結全球。

智慧醫學專題中心

協助智慧醫學相關大數據研發、發展精準醫療，以提升社會整體利益。將結合本院「臺灣人體生物資料庫計畫」、「臺灣精準健康計畫 (TPHP)」、「癌症登月計畫」及其他生醫相關的大數據。在相關法規核准下，規劃「智慧醫療」相關單位、人員、團體前來利用。

創服育成專題中心

打造創新的生醫生態系，向前銜接優質基礎研究，向後攻佔商業化場域，落實化研為用，整合產官學研推動臺灣生技新創發展為目標。



目錄

議程 DAY1		01
議程 DAY2		02
活動平面圖		03
Day1 Keynote Address		04
Day1 Executive Forum		06
Day2 Keynote Address		09
Day2 Executive Forum		11
Featured Presentation		12
One-on-One Partnering		15
Talent Match		16
Resume Consultation		17
Pitch Competition		18 - 41
Poster Showcase		42
交通資訊		44



— DAY 1 JULY 13 Monday —

Time	Program	Concurrent Activities
09:00 - 10:00	Registration	
10:00 - 10:15	Opening Remarks Chien-Jen Chen, President, Academia Sinica Chien-Chang Chen, Director, Biomedical Translation Research Center (BioTReC), Academia Sinica Tsai-Kun Li, President, Development Center for Biotechnology (DCB)	
10:15 - 10:25	Guest Remarks Ting-An Wang, Executive Secretary, National Development Fund, Executive Yuan Chih-Kang Chiang, Director General, Taiwan Food and Drug Administration (TFDA)	
10:25 - 10:30	Group Photo	
10:30 - 11:10	Keynote Address Rudi Pauwels, Founder & President, Praesens Foundation Moderator: Tsai-Kun Li, President, DCB	
11:10 - 11:15	Coffee Break	
11:15 - 12:00	Executive Forum Reshaping Taiwan's Biotech Ecosystem: Driving Industry Globalization Rudi Pauwels, Founder & President, Praesens Foundation Yiu-Lian Fong, PhD, MBA – Senior Strategic/Scientific Adviser, MiRXES; Founder, DxRxPM Biotech Consulting LLC Hiroki Narita, President & CEO, DCI Partners Michael Huang, Managing Partner of Bio Fund, Taiwan Capital Harvey Chin, Head of Global Strategy, PharmaEssentia Moderator: Michael Huang, VP, DCB	Company Exhibition Poster Showcase
12:00 - 13:00	Networking Lunch	
13:00 - 13:30	Therapeutics Pitch	One-on-One Partnering
13:30 - 13:50	Therapeutics Q&A	
13:50 - 14:10	Networking & Coffee Break	
14:10 - 14:40	Medical Device Pitch	
14:40 - 15:00	Medical Device Q&A	
15:00 - 15:20	Networking & Coffee Break	
15:20 - 15:55	Australian Innovation Showcase	
15:55 - 16:10	Australian Showcase Q&A	
16:10 - 16:40	Awards Ceremony	



— DAY 2 JULY 14 Tuesday —


Time	Program	Concurrent Activities
09:00 - 10:00	Registration	
10:00 - 10:35	Keynote Address Matthew Porteus, M.D., Ph.D., Director, Center for Definitive and Curative Medicine (CDCM), Stanford University Moderator: Alice Lin-Tsing Yu, Academician, Academia Sinica	
10:35 - 11:10	Executive Forum Early-Stage Translational Practices: Building an Express Strategy from Lab to First-in-Human Panelists: Matthew Porteus, M.D., Ph.D., Director, Center for Definitive and Curative Medicine (CDCM), Stanford University Yun Yen, Chair Professor & Emeritus President, Taipei Medical University Alice Lin-Tsing Yu, Academician, Academia Sinica Kotaro Funato, Partner, Health Industries Advisory, PwC Japan Ryan Potts, VP, Induced Proximity Platform, Amgen Moderator: Chien-Chang Chen, Director, BioTRC	
11:10 - 11:25	Networking & Coffee Break	Company Exhibition Poster Showcase
11:25 - 11:45	Overview of Government Biomedical R&D Resources Michael Huang, VP, DCB	
11:45 - 12:00	Taiwan Contract Research One-Stop Service: Introduction to T.CROSS Charlie Chen-En Cheng, Deputy Technical Director, National Center for Biomodels, NIAR	
12:00 - 13:30	Networking Lunch	
13:30 - 14:00	Therapeutics Pitch	Resume Consultation
14:00 - 14:20	Therapeutics Q&A	
14:20 - 14:40	Networking & Coffee Break	
14:40 - 15:10	Medical Device Pitch	
15:10 - 15:30	Medical Device Q&A	
15:30 - 15:50	Networking & Coffee Break	
15:50 - 16:20	Awards Ceremony	



— 樓層介紹 —

樓層平面圖


一樓平面圖



二樓平面圖



三樓平面圖





DAY 1

— Keynote Address —



Rudi Pauwels

Chairman, Praesens Foundation

Dr. Rudi Pauwels is a Belgian pharmaceutical scientist, virologist, biotech entrepreneur and Baron of Belgium whose career has moved repeatedly from scientific insight to global health impact. Trained as a pharmacist and awarded a Ph.D. in Pharmaceutical Sciences with greatest distinction from KU Leuven, he was among the early researchers working on HIV at the Rega Institute in Leuven.

His early work helped create laboratory screening models that enabled the discovery of new classes of antiretroviral medicines, including phosphonate nucleotide analogues such as PMEA, from which tenofovir-based therapies would later emerge, and the first non-nucleoside reverse transcriptase inhibitors. These discoveries became part of the scientific foundation for modern HIV treatment and prevention.

In 1994, Dr. Pauwels founded Tibotec, later acquired by Johnson & Johnson, where the pipeline produced several important HIV drugs, including darunavir, etravirine and rilpivirine. He also co-founded Virco, one of the earliest companies to bring personalized medicine into HIV care through resistance-guided therapy. Together, these innovations helped transform HIV from a rapidly fatal infection into a chronic, treatable condition for millions of people, while generating major medical and economic value across the global pharmaceutical sector.

After Tibotec-Virco, Dr. Pauwels founded Biocartis at EPFL in Lausanne, developing the Idylla molecular diagnostics platform: a fully automated sample-to-result, multiplex qPCR system designed to bring actionable molecular testing closer to patients. His later work expanded into epidemic preparedness through Praesens Foundation and Praesens Care, including mobile diagnostic laboratories for outbreak response.

Today, Dr. Pauwels is extending the same systems view of biology into prevention and healthy ageing. Through Helion Biosystems, based between Switzerland and Southern Spain, he is building a platform that combines controlled-environment agriculture, ISO-6 cleanroom production, freeze-drying, nutritional science and longevity research. The aim is to create precise, sustainable, bioactive nutrition that supports human resilience before disease begins.

Across pharmaceuticals, diagnostics, epidemic response and precision nutrition, Dr. Pauwels' work reflects one central conviction: biology is an interconnected system, and the future of health will depend on treating, detecting and preventing disease with equal scientific rigor.



DAY 1

— Keynote Address —



Moderator

Tsai-Kun Li

President, DCB

Prof. Li earned a bachelor's degree in Microbiology in Taiwan and received a US fellowship in 1994 for Ph.D. study in Molecular and Biochemical Pharmacology. He has established his research group since 2003 in "DNA topoisomerases and chromatin biology" in National Taiwan University College of Medicine and further extended his leadership in 2025 as the President of Development Center for Biotechnology (DCB), devoting himself to developments of new drug modalities as well as market-driven biotechnologies innovations and platforms. Moreover, his work has also contributed to key manufacturing and regulatory approvals, such as "Regenerative Medicine Act" and "Regenerative Medicinal Products Act". Additionally, Prof. Li with his DCB teams have focused on AI-enabled green chemistry using optimized bio-catalysis and biomanufacturing, subsequently aiming to transform the healthcare industry from Taiwan to global.



DAY 1

— Executive Forum —



Rudi Pauwels

Chairman, Praesens Foundation



Yiu-Lian Fong

Yiu-Lian Fong, PhD, MBA – Senior Strategic/Scientific Adviser, MiRXES; Founder, DxRxPM Biotech Consulting LLC

Dr. Yiu-Lian Fong is a veteran biotech and pharmaceutical executive and scientist with nearly 30 years of experience driving precision medicine initiatives at Novartis, Abbott, and Johnson & Johnson. She currently serves as a Senior Strategic and Scientific Adviser to MiRXES and as a Board Member/Adviser at Senhwa Biosciences. As the founder of DxRxPM Biotech Consulting, Dr. Fong leverages decades of therapeutic and medical device development leadership to guide biotechnology and diagnostic companies through the full product lifecycle, from developing early-stage target product profiles (TPP), business and partnership strategies, through the complex realities of regulatory pathways, clinical validation, reimbursement, and successful global commercialization.



Hiroki Narita

President & CEO, DCI Partners

Hiroki Narita is a distinguished venture capital professional currently serving as the President & CEO of DCI Partners Co., Ltd., that specializes in cross-border venture investments, with a primary focus on the life sciences sector.

A pivotal figure in forging financial and strategic corridors between Japan and Taiwan, Narita has played a central role in establishing bilateral investment platforms, including landmark strategic collaborations with the National Development Fund (NDF) of Taiwan. Under his leadership, DCI Partners has grown to manage the largest life science funds in Japan, serving as a critical catalyst in providing vital risk capital to high-potential startups.

Throughout a distinguished career, Narita has been deeply committed to shaping corporate governance and driving strategic development across the healthcare and biotechnology sectors. Leveraging this deep industry expertise, he currently serves as an outside director for both Surv Biopharma and C4U.



DAY 1

— Executive Forum —



Michael Huang

Managing Partner of Bio Fund, Taiwan Capital

Michael Huang is Managing Partner, Life Science Investment of Taiwan Capital Management Corp., where he leads life science and healthcare investment strategy across the United States, Taiwan, Japan, and Europe. He has more than 20 years of experience investing in and managing biotech and medtech companies, with a track record spanning early- to late-stage opportunities, portfolio governance, licensing, technology transfer, and exit planning.

Before joining Taiwan in 2018, he co-founded and served as CEO of NeuroVive Pharmaceutical Asia, a drug development company focused on mitochondria-related diseases, and completed licensing transactions with Sihan Pharmaceutical and Sanofi Korea. Earlier, he worked with CX Venture Capital Group, XCI Ventures, and TWI Pharmaceuticals. Michael holds an MBA from Rice University's Jesse H. Jones School of Management and an M.S. in Chemistry with honor from the University of Texas at Arlington.



Harvey Chin

Head of Global Strategy, PharmaEssentia

Dr. Yen-Po Harvey Chin, MD, PhD is Head of Global Strategy at PharmaEssentia USA, where he is responsible for the company's overall corporate strategy and investment functions. PharmaEssentia (TWSE: 6446) is a Taiwan-founded biopharmaceutical company with full in-house capabilities spanning R&D, clinical development, and commercialization in the US market. Operating across this full arc gives Dr. Chin a whole-value-chain perspective on drug development and commercialization, from which he helps bring Asian scientific innovation to international markets.

Previously, Dr. Chin was Executive Chairman of AGMI Group, a management consulting firm serving life science companies on M&A, portfolio, and commercial strategy. Before that, he was a consultant at McKinsey & Company's Boston office, advising biopharmaceutical, medical device, and private equity clients.

Dr. Chin holds an MD from National Yang Ming Chiao Tung University, a Master's in Biomedical Informatics from Harvard Medical School, and a PhD in Biomedical Informatics from Taipei Medical University. He was a member of the inaugural cohort of Harvard University's Healthtech Innovation Fellowship, the first Taiwanese physician selected to the Forbes 30 Under 30 Asia list, and co-author of From Bench to Market: A Biotech Valuation and Forecasting Playbook.



DAY 1

— Executive Forum —



Moderator

Michael Huang

VP, DCB

Dr. Michael Huang is a prominent leader in Taiwan's biotechnology and pharmaceutical sectors. He currently serves as the Director of the Biotechnology and Pharmaceutical Industries Promotion Office (BPIPO) and Vice President of the Development Center for Biotechnology (DCB), driving industry growth and global collaborations.

With extensive experience in pharmaceutical R&D and commercialization, Dr. Huang has held key leadership positions, including Head of the Institute of Drug Evaluation at DCB and international roles such as Group Leader-Principal Research Scientist at Pfizer and Wyeth Research in the U.S.

In academia, he was an Assistant Professor at the New Jersey Institute of Technology. Dr. Huang earned his Ph.D. in Chemical Engineering from the University of Massachusetts, Amherst, and holds Master's and Bachelor's degrees from National Taiwan University. He regularly mentors early-stage biotech ventures, helping them bridge innovation with global investment, and he continues to lead strategic initiatives that advance Taiwan's innovative biotechnology ecosystem.



DAY 2

— Keynote Address —



Matthew Porteus

M.D., Ph.D., Director, Center for Definitive and Curative Medicine (CDCM), Stanford University

Matthew Porteus MD, PhD is the Sutardja Chuk Professor of Definitive and Curative Medicine and a Professor in the Department of Pediatrics, Institute of Stem Cell Biology and Regenerative Medicine and Maternal-Child Health Research Institute at Stanford. He is clinically trained in pediatric bone marrow transplantation. He is the Director of the Stanford Center for Definitive and Curative Medicine and the co-Executive Director of the Stanford Cell and Gene Therapy GMP Facility called the Laboratory for Cell and Gene Medicine. He will serve as President of ASGCT from 2026-2027. His primary research focus is on developing genome editing as an approach to cure disease, particularly those of the blood (most notably sickle cell disease) but also of other organ systems as well. He was a scientific founder of CRISPR Tx and founder of Kamau Tx and serves on the Board of Directors of Arbor Bio and the scientific advisory boards of Biogen, Allogene, and Dispatch. He is a strong advocate for assuring that the next generation of transformative medicines reaches the global community in partnership with those communities.



DAY 2

— Keynote Address —



Moderator

Alice Lin-Tsing Yu

Academician, Academia Sinica

Alice L. Yu, M.D., Ph.D. is an Academician of Academia Sinica in Taiwan, currently a Distinguished Chair Professor at the Institute of Stem Cell & Translational Cancer Research in Chang Gung Memorial Hospital & Professor Emeritus of Pediatrics at the University of California in San Diego where she served as the Chief of Pediatric Hematology Oncology. She obtained MD from National Taiwan University, PhD in Microbiology and Immunology from University of Chicago. Dr. Yu is a pioneer in developing anti-GD2 mAb (Dinutuximab), culminating in its FDA approval for the treatment of high-risk neuroblastoma in 2015, marking the first immunotherapeutic agent targeting a glycolipid antigen. Treatment with anti-GD2 has since become standard of care for high risk neuroblastoma. She received Pediatric Oncology Award from the American Society of Clinical Oncology (ASCO) in 2020 and Lifetime Achievement Award from the Advances in Neuroblastoma Research Association in 2025.



DAY 2

— Executive Forum —



Matthew Porteus

M.D., Ph.D., Director, Center for Definitive and Curative Medicine (CDCM), Stanford University



Yun Yen

Chair Professor & Emeritus President, Taipei Medical University

Yun Yen, M.D., Ph.D., F.A.C.P., F.A.S.C.O., is a world-renowned oncologist, cancer researcher, and subject matter expert in ribonucleotide reductase (RR), whose pioneering studies elucidated the enzyme's role in DNA synthesis and repair. Over his distinguished academic career, he has published more than 400 articles in high-impact peer-reviewed journals and holds over 60 patents.

Dr. Yen serves as President Emeritus of Taipei Medical University (TMU), where he previously served as President from 2011 to 2017, and is currently a Chair Professor. His extensive institutional background includes 22 years at City of Hope's Comprehensive Cancer Center, serving as Associate Director and Chair of Molecular Pharmacology. Additionally, he holds appointments at Academia Sinica, California Institute of Technology, and Case Western Reserve University. Currently, he serves as President of the Taiwan Biomedical Innovation Association (TiBIA).



Alice Lin-Tsing Yu

Academician, Academia Sinica



DAY 2

— Executive Forum —



Kotaro Funato

Partner, Health Industries Advisory, PwC Japan

Kotaro Funato is a Managing Director and Executive Officer at PwC Japan, with a focus on healthcare, pharmaceuticals, and life sciences. Prior to joining PwC, he worked at a major consulting firm and held positions at several multinational pharmaceutical companies.



Ryan Potts

Ph.D., Vice President, Research, Head, DATA (Discovery Science, Advanced Technologies, and AI), Chair, R&D Postdoc Program, Amgen, Inc.

Ryan Potts obtained his Ph.D. in Cell and Molecular Biology from UT Southwestern in 2007. In 2008 he was awarded the Sara and Frank McKnight junior faculty position at UT Southwestern Medical Center and appointed as Assistant Professor in the Departments of Physiology, Pharmacology, and Biochemistry in 2011. In 2016 his lab moved to St. Jude Children's Research Hospital where he was an Associate Member in the Department of Cell and Molecular Biology. In 2020, he moved to Amgen as Executive Director of Research and Head of the Induced Proximity Platform that is focused on empowering multi-specific, induced proximity therapeutic modalities through bold, creative science to expand the druggable genome and reimaging the future of drug discovery. In 2021, he took over leadership of Amgen's Postdoctoral Fellows Program aimed at training the next generation of industry scientists. In recognition to his important contributions at Amgen, he was promoted to Vice President in 2023 with an expanded role to oversee multiple technology focused platforms with the Research Technologies department. In 2025, his role expanded to oversee a new Research function, DATA (Discovery Science, Advanced Technologies, and AI).



DAY 2

— Executive Forum —



Moderator

Chien-Chang Chen

Director, BioTReC

Dr. Chien-Chang Chen works in the field of physiology, with his research focusing on the mechanisms underlying the development of persistent chronic pain using optogenetics, chemogenetics, in vivo imaging, gene targeting, electrophysiological, pharmacological and behavioral approaches in wild type and genetically modified mice. Dr. Chen's early studies at IBMS focused on understanding the role of T-type Ca^{2+} channels in brain and cardiovascular system, especially related to human diseases such as cardiac ischemia- reperfusion injury, cardiac hypertrophy, platelet function and pain sensation. For the past ten years, however, Dr. Chen's laboratory has actively investigated the role of the anterior nucleus of paraventricular thalamus (PVA) in chronic pain and the formation of hyperalgesia priming. Dr. Chen's studies show that PVA is involved in the development and maintenance of chronic in several rodent models. Dr. Chen also investigates the underlying mechanism for the transition from acute pain to chronic pain. Dr. Chen received his Ph.D. in Physiology and Biophysics from University of Illinois at Urbana-Champaign and post-doctoral training in ion channel and mouse genetics at Howard Hughes Medical Institute at University of Iowa.

Dr. Chen accepted a faculty position as an Assistant Research Fellow at the Institute of Biomedical Sciences at Academia Sinica in 2005, earning promotion to Associate Research Fellow in 2011 and to Research Fellow/Professor in 2018. Dr. Chen served as the Director of the Department of International Affairs from 2019-2020. He is currently the Director of the Department of Academic Affairs and Instrument Services at Academia Sinica.



DAY 2 — 專題演講 —



Michael Huang

VP, DCB

Dr. Michael Huang is a prominent leader in Taiwan's biotechnology and pharmaceutical sectors. He currently serves as the Director of the Biotechnology and Pharmaceutical Industries Promotion Office (BPIPO) and Vice President of the Development Center for Biotechnology (DCB), driving industry growth and global collaborations.

With extensive experience in pharmaceutical R&D and commercialization, Dr. Huang has held key leadership positions, including Head of the Institute of Drug Evaluation at DCB and international roles such as Group Leader-Principal Research Scientist at Pfizer and Wyeth Research in the U.S.

In academia, he was an Assistant Professor at the New Jersey Institute of Technology. Dr. Huang earned his Ph.D. in Chemical Engineering from the University of Massachusetts, Amherst, and holds Master's and Bachelor's degrees from National Taiwan University. He regularly mentors early-stage biotech ventures, helping them bridge innovation with global investment, and he continues to lead strategic initiatives that advance Taiwan's innovative biotechnology ecosystem.



Charlie Chen-En Cheng

Deputy Technical Director,
National Center for Biomodels, NIAR

Chen-En Cheng, D.V.M., M.Sc., DABT, ERT, UKRT is the Associate Researcher at the National Institutes of Applied Research, National Center for Biomodels, Taiwan. Dr. Cheng received his master's degree in veterinary medicine from the National Taiwan University, Taipei, Taiwan. He has over 20 years of experience in preclinical safety assessment and toxicology, with leadership responsibilities in strategic new drug development planning, cross-functional resource integration, and R&D management. He is currently a member of AAALAC International Council of Accreditation.



— One-on-One Partnering —

Takeda (武田藥品工業株式會社)

Takeda (武田藥品) 創立於 1781 年，全球總部位於日本東京，是日本最大的研發型生物製藥公司，也是國際領先的創新藥廠之一。2019 年完成對 Shire 的收購後，Takeda 進一步擴大研發與商業布局，目前業務遍及約 80 個國家及地區。秉持「Better Health for People, Brighter Future for the World」的企業宗旨，Takeda 致力於透過創新科學研發突破性療法，持續提升病患的健康與生活品質。

Takeda 以創新研發為核心，聚焦於胃腸與發炎疾病 (Gastroenterology & Inflammation)、罕見疾病 (Rare Diseases)、血漿衍生療法 (Plasma-Derived Therapies)、腫瘤 (Oncology)、神經科學 (Neuroscience) 及疫苗 (Vaccines) 等重點治療領域，持續推動具臨床價值的新藥開發，並藉由全球研發體系加速創新療法的研發、臨床轉譯與上市進程。

在創新合作方面，Takeda 長期推動開放式創新 (Open Innovation)，透過共同研究、技術授權、策略聯盟及外部創新夥伴合作，攜手學術機構、生技公司與新創企業，共同推進醫療創新發展。藉由整合全球創新資源與內部研發能力，Takeda 持續拓展合作網絡，提升研發效能，加速新藥開發，讓更多病患受惠於創新治療方案。

Boehringer Ingelheim (德國百靈佳殷格翰藥廠兩合公司)

Boehringer Ingelheim (BI, 百靈佳殷格翰) 創立於 1885 年，總部位於德國 Ingelheim am Rhein，為全球最大的家族經營製藥公司之一，業務遍及 130 多個國家，致力於透過創新藥物研發改善人類與動物健康，並以研發驅動 (Research-driven) 作為企業發展核心。

在人用藥研發方面，BI 聚焦於心血管、腎臟與代謝疾病 (Cardiovascular, Renal and Metabolic Diseases)、腫瘤 (Oncology)、免疫疾病 (Immunology)、眼科 (Eye Health) 及心理健康 (Mental Health) 等重點治療領域，並透過持續深化對疾病機制的理解，推動具臨床價值的創新療法開發。

BI 積極推動開放式創新與全球合作，透過 Human Health Partnering、BI X、opnMe 及 Boehringer Ingelheim Venture Fund (BIVF) 等平台，與全球學術機構、生技公司及新創團隊建立合作夥伴關係。合作模式涵蓋共同研發、技術授權及策略投資，期望透過跨領域合作加速創新技術開發，將具潛力的研究成果推向臨床應用與全球市場。



Talent Matching

2026 人才媒合啟動 | 鏈結生醫人才與團隊需求，打造下一波成長動能

為回應生醫產業、新創團隊與學研轉譯團隊之人才需求，2026 活動將同步辦理人才媒合交流，邀請有招募需求之企業、團隊、機構與有意投入生醫創新領域之專業人才共同參與。

媒合範圍涵蓋研發、臨床、法規、商務開發、智財、製造、專案管理、市場拓展等產官學研多元職能，協助用人單位找到關鍵夥伴，也協助人才找到能發揮影響力的舞台。





— Resume Consultation —

本次履歷健檢活動，我們特別邀請了三位來自生技醫藥、醫療科技與職涯諮詢領域的重量級業界專家。他們將以最犀利的 HR 視角與豐富的實務經驗，親自為履歷把脈、梳理職涯定位，精準打造具競爭力的個人品牌！

以下為本次活動的黃金導師陣容（依姓氏筆畫排序）：

職涯導師陣容介紹

吳翊菱

智擎生技製藥股份有限公司 人資經理

現任生技醫藥產業人資主管，具招募甄選、人才發展與職涯諮詢經驗。熟悉新藥研發產業人才需求，擅長從 HR 與職涯設計觀點，協助求職者優化履歷、梳理職涯定位並提升面試表達力。

劉彥志

臺北醫學科技 X TFC 臺北生殖中心 人資長

具備多年生醫、醫療器材及消費健康產業管理經驗，曾任生醫公司營運長及多家企業人資長，專長涵蓋組織發展、人才策略與營運管理。熟悉快速成長企業的人才佈局，能結合商業策略引導求職者看見產業全貌。

謝瑋宸

吉晟生技公司 資深工程師 / CDA 國際生涯發展諮詢師

現任吉晟生技資深工程師，歷練藥廠產線主管與 QA 品質系統。兼具 CDA 國際認證的他，已累積逾 50 位履歷健診實績，擅長以理性分析引導技術人才突破職涯盲點、精準規劃生涯。

把握與高階人資主管及資深諮詢師一對一對談的珍貴機會，名額有限，請準備好您的履歷，讓我們一起翻轉職涯新高度！

履歷健診服務





Pitch Competition



Innovation · New Therapeutics

安宏生醫股份有限公司 AnHorn Medicines Co., Ltd.

技術名稱

全球首創預防化療導致周邊神經病變新藥

First in class prevention therapy for Chemotherapy-Induced Peripheral Neuropathy(CIPN)

技術領域

新藥開發 New Drug Development

發展階段

臨床一期 Clinical Phase I

技術 / 產品簡介

AH-008 is a first-in-class, Phase I-ready neuroprotective drug candidate developed to prevent chemotherapy-induced peripheral neuropathy (CIPN), a common and debilitating complication associated with widely used cytotoxic chemotherapies and antibody-drug conjugates (ADCs), including taxanes and platinum-based agents. By protecting peripheral nerves from chemotherapy-induced damage, AH-008 has the potential to preserve patients' quality of life, reduce treatment-related morbidity, and enable optimal chemotherapy dosing and treatment adherence, addressing a significant unmet medical need in oncology supportive care.



Pitch Competition



長弘生物科技股份有限公司 Everfront Biotech

技術名稱

Cerebraca® Wafer：用於復發膠質母細胞瘤的新型局部治療

Cerebraca® Wafer: A Novel Local Therapy for Recurrent Glioblastoma

技術領域

新藥開發 New Drug Development

發展階段

臨床二期 Clinical Phase II

技術 / 產品簡介

Cerebraca Wafer is a biodegradable, sustained-release surgical adjunct for glioblastoma, placed into the resection cavity to deliver a multi-targeted small molecule. By bypassing the blood-brain-barrier and achieving tissue penetration up to 6.5-cm, it eliminates residual infiltrating tumor cells, reverses MGMT-mediated chemoresistance, and significantly extends survival beyond current standards of care.



Pitch Competition

佳揚生物科技股份有限公司 PapiVax Biotech, Inc.

技術名稱

從病毒感染到癌症治療的核酸精準治療

Precision Nucleic Acid Therapeutics: From Viral Infection to Cancer Treatment

技術領域


細胞治療 / 基因治療 Cell/Gene Therapy

發展階段

臨床二期 Clinical Phase II

技術 / 產品簡介

PVX4 is a next-generation DNA immunotherapy integration targeting a \$27.9B market. Validated by US FDA/TFDA, it delivers an 80% clearance rate for HPV16 infections and high-grade lesions—over 3x competitor efficacy. Utilizing the TriGrid system, this scalable platform efficiently targets high-risk HPV and aggressive RAS-mutant cancers with high specificity.





Pitch Competition



BELIMINATE

醫莉鎂生醫

醫莉鎂生醫 Beliminate Biotech

技術名稱

全新抗癌標靶 KIF2C 口服抑制劑 7S9 — 終結腫瘤多重抗藥性

A First-in-Class Oral KIF2C Inhibitor (7S9) Addressing Chemoresistance in TNBC with Combination Potential

技術領域

新藥開發 New Drug Development

發展階段

動物實驗 / 臨床前 Pre-clinical

技術 / 產品簡介

First-in-class oral KIF2C inhibitor 7S9 restores chemotherapy sensitivity in drug-resistant tumors, boosting paclitaxel efficacy over 200-fold in preclinical models. Targeting triple-negative breast cancer through a mechanism entirely distinct from approved therapies, 7S9 is advancing toward IND-enabling studies with a clear path to clinical translation.



Pitch Competition



光合生物醫學股份有限公司 Enlighten BioMedicine Co., Ltd.

技術名稱

PBX1 完全新創轉錄因子小分子藥物標靶抗性胰臟癌
Hunting the Root of Resistant PDACA

技術領域

新藥開發 New Drug Development

發展階段

動物實驗 / 臨床前 Pre-clinical

技術 / 產品簡介

Enlighten Biomedicine is developing B004, a first-in-class PBX1-targeting small molecule for resistant pancreatic cancer. By targeting cancer stem cell-linked relapse, metastasis, and drug resistance, B004 aims to build a biomarker-guided Pre-IND package for future licensing or co-development.



Pitch Competition

奈力生醫股份有限公司 Nano Targeting & Therapy Biopharma Inc.

技術名稱

中孔洞二氧化矽奈米粒子平台技術用於精準藥物輸送
A Novel Silica Nanocarrier Platform for Precision Drug Delivery

技術領域

精準醫療 / 診斷 Precision Medicine/Diagnostics

發展階段

動物實驗 / 臨床前 Pre-clinical

技術 / 產品簡介


NTT Biopharma's proprietary mesoporous silica nanoparticle (MSN) platform enables drug delivery across biological barriers (BBB/BOB), enhanced tumor targeting, deep tissue penetration, unique anti-metastatic activity, and non-invasive eyedrop delivery, advancing next-generation nanomedicines for CNS disorders, refractory cancers, and retinal diseases with improved therapeutic efficacy and safety.

Our Solution: MSN Platform Technology

MSNs are promising to overcome the key drug delivery challenges



奈力生醫股份有限公司
Nano Targeting & Therapy Biopharma Inc.





Pitch Competition

COHERENCE

擴核生醫科技股份有限公司 Coherence Biotech Co., Ltd.

技術名稱

用於多日細胞與類器官實驗的連續式實驗自動化系統
Continuous Lab Automation for Multi-Day Cell and Organoid Biology

技術領域

原型 / 實驗室驗證 Prototype/Lab Validation

發展階段

其他 Others

技術 / 產品簡介

Keystone is a benchtop system for continuous lab automation. It integrates incubation, liquid handling, and imaging so multi-day cell and organoid experiments stay on one controlled timeline and one traceable record — letting teams tell real biology from execution noise.



Pitch Competition

諾研生醫股份有限公司 NORIEN BIOTECH

技術名稱

OsteoFill Gel™ - 局部精準藥物投遞與緩釋水凝膠平台

OsteoFill Gel™-Localized Precision Drug Delivery and Sustained-Release Hydrogel Platform

技術領域

動物實驗 / 臨床前 Pre-clinical

發展階段

精準醫療 / 診斷 Precision Medicine/Diagnostics

技術 / 產品簡介

OsteoFill Gel is an injectable sustained-release hydrogel platform designed for localized precision drug delivery, bone defect filling, and infection control, providing a biocompatible scaffold that supports bone repair while enabling prolonged therapeutic release at the target site.





Pitch Competition

光大科技股份有限公司 QUANTA VISION Inc.

技術名稱

毒品唾液智慧檢測系統
Drug Testing Oral Fluid Screening

技術領域

動物實驗 / 臨床前 Pre-clinical

發展階段

其他 Others

技術 / 產品簡介

A smart, non-invasive oral fluid drug screening system that utilizes AI-calibrated optical diagnostics and advanced immunochromatography to deliver rapid, multi-analyte results within minutes, customized capabilities for detecting emerging substances like etomidate e-liquids.





Pitch Competition

博鍊生技股份有限公司 Plexbio Co., Ltd.

技術名稱

無需體外培養之全血敗血症病原體與抗藥性基因全自動化定點照護檢測平台
Culture-Free, Sample-to-Result Sepsis Pathogen & AMR POCT Platform

技術領域

概念 / 研究階段 Concept/Research


發展階段

體外診斷 IVD

技術 / 產品簡介

A scalable molecular platform designed to deliver broad pathogen and AMR information directly from whole blood within the early sepsis treatment window.

PlexBio πCode™ MicroDiscs Technology





Pitch Competition



蔚流生物科技股份有限公司 Fluidiconic Biotechnology Co., Ltd.

技術名稱

藥選能：人類腫瘤智慧平台用於藥物開發
MedSelect® The Human Tumor Intelligence Platform

技術領域

已取得上市許可 / 銷售中 Marketed

發展階段

精準醫療 / 診斷 Precision Medicine/Diagnostics

技術 / 產品簡介

MedSelect is a functional oncology platform that recreates the human tumor microenvironment to predict drug response and improve drug development decisions.



Pitch Competition

迪利歐生醫 Delyo

技術名稱

安心引流系統
AnXin Drainage System

技術領域

原型 / 實驗室驗證 Prototype/Lab Validation

發展階段

微創 / 介入性醫材 Minimally Invasive/Interventional Devices

技術 / 產品簡介

AnXin is an active chest drainage system for post-cardiac-surgery patients. A motor-driven helical catheter clears fibrin clots inside the drain tube while nine embedded sensors continuously monitor patency. Real-time data enables early occlusion detection and predictive intervention, reducing retained blood syndrome risk and eliminating manual stripping.





Pitch Competition

醫療財團法人徐元智先生醫藥基金會亞東紀念醫院
Far Eastern Memorial Hospital

技術名稱

可踢肽®
CatiPep®

技術領域


新藥開發 (New Drug Development)

發展階段

動物實驗 / 臨床前 Pre-clinical

技術 / 產品簡介

CatiPep® is the world's first AI-engineered disease-modifying peptide for osteoarthritis, addressing the global unmet need for an approved DMOAD. By combining scientific innovation with a clear translational pathway, CatiPep® possesses significant clinical, commercial, and global market potential.





Pitch Competition

國立中興大學陳泰霖研究團隊 National Chung Hsing University

技術名稱

首創小分子 NPM1 降解劑 BO2768：急性骨髓性白血病精準治療的新契機

BO2768 A First-in-Class Small-Molecule NPM1 Degradar for Acute Myeloid Leukemia

技術領域

新藥開發 New Drug Development

發展階段

動物實驗 / 臨床前 Pre-clinical

技術 / 產品簡介

BO2768 is a first-in-class small-molecule NPM1 degrader designed for acute myeloid leukemia. By targeting both wild-type and mutant NPM1, BO2768 offers a novel therapeutic strategy to overcome current treatment limitations and improve precision leukemia therapy.

BO-2768: A First-in-Class NPM1 Inhibitor to Overcome Drug Resistance in Acute Myeloid Leukemia (AML)

BO-2768 is a first-in-class small molecule inhibitor that selectively targets nucleophosmin (NPM1)—a critical driver of leukemic cell survival in acute myeloid leukemia (AML).

OPPORTUNITY:

Targeted indication:


AML, particularly NPM1-mutated and drug-resistant AML

MOA :


- ✓ First-in-class small molecule targeting NPM1
- ✓ reduced FLT3-ITD signaling, disrupted KMT2A/menin interaction, and induced DNA damage
- ✓ Favorable safety profile and oral availability
- ✓ Overcoming drug resistance and minimal residual disease (MRD) by reducing leukemic stemness

EXPERIMENTAL RESULTS:

Target Engagement and Mechanism



In vivo efficacy:



Safety pharmacology and general toxicology:

No significant toxicity observed in blood chemistry or histopathology (heart, liver, kidney, lung, spleen) at doses up to 90 mg/kg.

Business Opportunity

License and/or Collaboration and
Sponsored Research

Follow-Up:

Please contact NCHU, Taiwan at chentl@nchu.edu.tw
Ta-Lin, Chen, Ph.D.
Drug Commercialization Center, TAIWAN at dcc@biip-dcc.org



Pitch Competition

國立清華大學先進放射新藥與 BNCT 轉譯研發團隊

Advanced Radiopharmaceutical & BNCT Translational Lab at NTHU

技術名稱

透過獲證專利的雙層 [^{18}F] 伴隨式診斷與劑型技術，輔以 100% 驗證的真實數據誠信，徹底消除硼中子捕獲治療 (BNCT) 的盲目投藥盲點

Eliminating the Blind Spot in BNCT Therapy Through Patented, Dual-Layer [^{18}F] Companion Diagnostics and Formulations with 100% Validated Data Integrity

技術領域


精準醫療 / 診斷 Precision Medicine/Diagnostics

發展階段

動物實驗 / 臨床前 Pre-clinical

技術 / 產品簡介

We develop patented [^{18}F]-labeled PEGylated boron-tryptophan variants as companion diagnostics for precision BNCT oncology. Our technology provides non-invasive, quantifiable in vivo pharmacokinetics, proven by high tumor-to-muscle contrast in tumor-bearing models. This eliminates blind dosing, de-risks clinical pipelines, and guides personalized radiation dosimetry.





Pitch Competition

中央研究院基因體中心洪上程研究團隊
Genomics Research Center, Academia Sinica

技術名稱

首創標靶 SULF2–GPC1 訊號軸的新一代胰臟癌與膽管癌治療策略

Developing a First-in-class Therapy Targeting the SULF2–GPC1 Signaling Axis for Pancreatic Cancer and Cholangiocarcinoma

技術領域


新藥開發 New Drug Development

發展階段

動物實驗 / 臨床前 Pre-clinical

技術 / 產品簡介

We developed a first-in-class trisaccharide SULF2 inhibitor targeting the SULF2–GPC1 signaling axis. The inhibitor suppresses tumor growth and metastasis by inhibiting AKT/ERK signaling and reversing EMT, demonstrating strong therapeutic potential for pancreatic cancer and cholangiocarcinoma.





Pitch Competition

國立臺灣大學核酸醫學中心張智芬研究團隊

Center of Nucleic Acid Medicine, National Taiwan University

技術名稱

一種修飾 mRNA 編碼粒線體表面工程化的病毒 RNA 降解劑作為廣譜抗病毒劑

A Modified mRNA Encoding an Engineered Viral RNA Degradator on Mitochondrial Surface as a Broad-Spectrum Anti-viral Agent

技術領域

新藥開發 (New Drug Development)


發展階段

原型 / 實驗室驗證 Prototype/Lab Validation

技術 / 產品簡介

ENDOg nuclease leakage from mitochondria mitigates vRNA replication at Mito/ER spheres. Engineering ENDOg on mitochondrial surface shows a broad-spectrum anti-viral activity against VSV, Influenza, Dengue, and Zika virus replication.

An Engineered MOM-ENDOG Degrades Viral RNA on Mitochondrial Surface





Pitch Competition

中央研究院應用科學研究中心董奕鍾研究團隊 TungLab.RCAS.AS

技術名稱

桌上型 mRNA 製劑工廠
Bench top mRNA factory

技術領域

其他 Others


發展階段

原型 / 實驗室驗證 Prototype/Lab Validation

技術 / 產品簡介

A compact, on-demand bioprocessing platform for patient-specific mRNA therapeutics.

Continuous IVT Bioreactor



Column Switching Purification





Pitch Competition

臺北榮民總醫院功能性神經外科李政家研究團隊

Taipei Veterans General Hospital / Department of Functional Neurosurgery

技術名稱

定位顱內電極的方法和系統

METHOD AND SYSTEM FOR LOCALIZING IMPLANTED INTRACRANIAL ELECTRODE

技術領域

AI 醫療 AI in Healthcare

發展階段

概念 / 研究階段 Concept/Research

技術 / 產品簡介

Method and system for intracranial electrode localization using image registration and brain atlas mapping to identify electrode contacts and their corresponding functional brain regions.

姓名：李政家 周建成 尤香玉
職稱：主治醫師
科部：神經醫學中心
得獎作品：定位顱內電極的方法與系統

優 良 事 蹟

立體定位腦電波電極置放術做為一種侵入性的腦波研究方式，常用於對癲癇藥物無效之癲癇。立體定位腦電波電極置放術可以精確地紀錄深部的皮質及皮質下結構，也可用於多發性、非連續之腦葉病灶，更可以同時紀錄兩側大腦半球的腦電波。立體定位腦電波電極置放術在設計之初是一多工且複雜的程序。因為其技術上的複雜性，直到近年神經影像成像的技術進步，以及對立體定位手術的熟悉度，立體定位腦電波電極置放術才成為世界上各個癲癇治療中心，是一個深入腦部尋找癲癇放電點的一個重要手術方式。

本定位顱內電極的方法與系統經過多年的跨科合作，發展出一套自動標記深部電極於大腦功能區的技術，自動標示深部電極的位置及其相對應腦區的方式，利用已建立的 Brodmann area 腦皮質分區、神經纖維束與深部灰質分區，自動標記深部電極於大腦解剖位置，進而標準化癲癇病人的致癲灶及功能區，進一步幫助臨床醫師、技術人員與癲癇研究團隊更了解電極解剖位置、與大腦各功能分區在癲癇發作的迴路中所扮演的角色。此技術目前已實際應用於臨床上癲癇，不只限於表面皮質腦區，還包括下皮質區、白質區、及深部核區，有助於癲癇網絡的重建，讓癲癇手術更安全、研究 方向更明確；此外，我們也可應用於其他需要深部腦刺激、及有置入電極需求的疾病，如巴金森氏症、顫抖症等。此方法已成功取得國內外之專利，過去刊登於本院臨床醫學月刊並為本科醫師現行之上課教材，也順利發表於重要之 SCI 期刊。

美國專利：METHOD AND SYSTEM FOR LOCALIZING IMPLANTED INTRACRANIAL ELECTRODE (US patent Application number:16/368,845)
 台灣專利：定位顱內電極的方法及系統 (中華民國專利證書: 發明第I680744號)



Pitch Competition

國立陽明交通大學張牧新研究團隊
National Yang Ming Chaio Tung Univerisity

技術名稱

Spongy Hydrogel™ 精準腫瘤藥物預測系統
Spongy Hydrogel™ Foundry for Precision Oncology

技術領域

精準醫療 / 診斷 Precision Medicine/Diagnostics

發展階段

原型 / 實驗室驗證 Prototype/Lab Validation

技術 / 產品簡介

Spongy Hydrogel™ Foundry for Precision Oncology unites a proprietary porous 3D tumoroid culture system with a physics-informed AI engine to model patient-specific drug response. Tumor-agnostic and scalable across solid tumors, it transforms each patient's living tumor into a functional, quantitative drug-sensitivity readout.





Pitch Competition



臺北醫學大學曾厚教授團隊 Prof. How Tseng's Team

技術名稱

新興片狀細胞工程於關節軟骨重建之應用

Advanced Bioengineering of Cell Sheets for Articular Cartilage Reconstruction

技術領域

細胞治療 / 基因治療 Cell/Gene Therapy

發展階段

動物實驗 / 臨床前 Pre-clinical

技術 / 產品簡介

Our patented, redox-responsive cell sheet platform bypasses traditional thermo-responsive limits. By grafting gamma-PGA and disulfide linkers, it achieves a biomimetic stiffness of 16.2 MPa to suppress chondrocyte dedifferentiation. Utilizing a mild reducing agent allows non-enzymatic harvesting of intact, matrix-rich sheets, driving robust hyaline cartilage regeneration.



Pitch Competition

睿識智醫 RADAX.AI

技術名稱

腦動脈瘤人工智慧偵測、量化與風險分層技術

AI-Powered Brain Aneurysm Detection, Quantification, and Risk Stratification Technology

技術領域

AI 醫療 AI in Healthcare

發展階段

臨床三期 Clinical Phase III

技術 / 產品簡介

Brain aneurysms stay silent until rupture causes death or lifelong disability. Yet the scans that could reveal them are often read once and forgotten. RDX-Aneurysm gives every MRA a second chance, finding missed aneurysms and helping clinicians decide who needs treatment or closer follow-up before it is too late.





Pitch Competition

國立中山大學海洋生物醫學實驗室溫志宏研究團隊 Marine Biomedical Lab

技術名稱

利用養殖耐熱型銳枝鹿角珊瑚製備之永續骨材與其專利燒結技術

Sustainable Cultivated Heat-resistant Pocillopora acuta Coral-Derived Sintered Biomaterial for Enhanced Bone Regeneration

技術領域

植入式醫材 Implantable Devices

發展階段

動物實驗 / 臨床前 Pre-clinical

技術 / 產品簡介

This technology leverages sustainably cultivated heat-resistant Pocillopora acuta coral to develop a high-performance bone graft. Optimized through a specialized sintering process, it transforms into a highly porous calcite structure that significantly enhances osteoconduction, accelerates preosteoblast proliferation, and promotes superior in vivo bone healing while maintaining excellent biocompatibility.



Pitch Competition

國立成功大學整合機械生物系統實驗室 GelAtlas 團隊

GelAtlas Team, Integrated Mechanobiosystems Lab, National Cheng Kung University

技術名稱

GelAtlas：水膠式三維組織培養、影像分析與組織回收平台

GelAtlas: A Hydrogel-Based 3D Tissue Culture, Imaging, and Tissue Recovery Platform

技術領域

其他

發展階段


原型 / 實驗室驗證 Prototype/Lab Validation

技術 / 產品簡介


GelAtlas is a hydrogel-based 3D tissue culture platform enabling stable tissue positioning, high-resolution imaging, dynamic culture, and intact tissue recovery for reproducible drug testing workflows.

GelAtlas

- ✓ Multiple chip formats available: single-chip design, 3-chamber integrated chip, and 18-chamber platform compatible with a standard 96-well plate footprint.
- ✓ Precise cell culture positioning on-chip, enabling reproducible experiments and high-resolution confocal imaging.



- ✓ Flexible geometries that can be customized to accommodate diverse experimental designs and biological applications.
- ✓ Dynamic culture capability with perfusion systems, featuring a removable cap design that enables convenient open-close operation for tissue loading, culture, retrieval, and downstream analysis.





Poster Showcase

DEMO DAY

藥品領域



團隊名稱	題目
長弘生物科技股份有限公司	Cerebraca® Wafer: 用於復發膠質母細胞瘤的新型局部治療
醫莉鎂生醫團隊	全新抗癌標靶 KIF2C 口服抑制劑 7S9 — 終結腫瘤多重抗藥性
凱恩生醫股份有限公司	微循環再生治療平台
奈力生醫股份有限公司	中孔洞二氧化矽奈米粒子平台技術用於精準藥物輸送
博蔚醫藥生物科技股份有限公司	減脂保肌新藥CAL010 (adipocyte-specific)、 發炎性腸炎奈米抗體CAL005 (innate immunity)

醫材領域

團隊名稱	題目
思靈客創集科技股份有限公司	結合 N-DNA™ 半導體生醫晶片與 EvoRisk™ 人工智慧 L1 成長記憶層之 CKM (心腎代謝) 預測醫學實時訊號平台
安美洛生醫股份有限公司	RealSeal 黃金救援時間止血技術
芯元生醫股份有限公司	Genimer: 以AI輔助實現精準高純度外泌體純化平台
諾研生醫股份有限公司	OsteoFill Gel™-局部精準藥物投遞與緩釋水凝膠平台
諭泰生物技術股份有限公司	腫瘤微環境晶片
蔚流生物科技股份有限公司	藥選能: 人類腫瘤智慧平台用於藥物開發
全域醫學科技股份有限公司	智慧脊椎內視鏡影像即時分析平台
愛而生股份有限公司	智慧吸入裝置-慢性呼吸道數位醫療照護
碩泰生醫有限公司	一種基於CMOS生醫晶片之低損傷細胞轉染平台
博鍊生技股份有限公司	無需體外培養之全血敗血症病原體與抗藥性基因全自動化定點照護檢測平台
李克生物科技股份有限公司	高效平地馴化與成分優良定向選育新品種虎杖與低溫穿壁微粉化技術: 全方位攻克燒燙傷異常蛋白(燒傷毒素)之 植物新藥、OTC中藥成藥及皮膚修復製劑開發計畫
信標生醫股份有限公司	多體學液體活檢
迪利歐生醫團隊	安心引流系統



Poster Showcase

PITCH DAY

藥品領域



團隊名稱	題目
醫療財團法人徐元智先生醫藥基金會亞東紀念醫院廖秀蓉研究團隊	可踢肽®
科思塔醫療團隊	紅血球細胞膜載體用於體內T細胞治療
國立清華大學先進放射新藥與BNCT轉譯研發團隊	透過獲證專利的雙層 [^{18}F] 伴隨式診斷與劑型技術，輔以100% 驗證的真實數據誠信，徹底消除硼中子捕獲治療(BNCT)的盲目投藥盲點
中央研究院基因體中心洪上程研究團隊	首創標靶 SULF2-GPC1 訊號軸的新一代胰臟癌與膽管癌治療策略
中央研究院應科中心董奕鍾研究團隊	桌上型 mRNA 製劑工廠

醫材領域

團隊名稱	題目
臺北醫學大學曾厚教授研究團隊	新興片狀細胞工程於關節軟骨重建之應用
國立中山大學海洋生物醫學實驗室溫志宏研究團隊	利用養殖耐熱型銳枝鹿角珊瑚製備之永續骨材與其專利燒結技術

生模中心

團隊名稱	題目
國家實驗研究院國家生物模式中心	專業職能再造 3R落地生根
國家實驗研究院國家生物模式中心	生醫研究的造夢者
國家實驗研究院國家生物模式中心	高齡多重共病動物模式

食藥署

團隊名稱	題目
衛生福利部食品藥物管理署	2026國家藥物科技研究發展獎
衛生福利部食品藥物管理署	Journal of Food and Drug Analysis



— 交通資訊 —

大眾運輸

園區公車

(1) 通勤公車：

通勤 16 主線 (捷運南港展覽館站)，經捷運南港展覽館一號口 (公車站牌：經貿二路站)、捷運南港站二號出口對面 (公車站牌：捷運南港站)、國家生技研究園區 (A/C 棟、F 棟)
時間：07:10~08:50、17:05~19:05；

通勤 16 支線 (捷運南港站)，經捷運南港站二號出口對面 (公車站牌：捷運南港站)、國家生技研究園區 (A/C 棟、F 棟)

時間：07:30~08:40、16:40~18:20

(2) 免費接駁專車：

經捷運南港展覽館一號口 (公車站牌：經貿二路站)、捷運南港站二號出口對面 (公車站牌：捷運南港站)、國家生技研究園區 (A/C 棟、F 棟)、中央研究院
時間：09:00~17:00

(3) 園區周邊公車：

205、212 直行忠孝東路、212 夜間公車、212 經南港路、270、270 區間車、306、306 區間車、620、645、645 區間車、679、679 區間車、藍 25、小 1、小 5、小 12、小 12 區間車、小 12 延駛動物園 (* 至圓拱橋站) 至「圓拱橋站」下車後，轉入研究院路二段 12 巷，步行約 400 公尺即為國家生技研究園區南側大門

火車 / 高鐵

至「南港火車站」轉乘公車：306、205、276、小 12、212、679、小 5 (* 至圓拱橋站) 至「圓拱橋站」下車後，轉入研究院路二段 12 巷，步行約 400 公尺即為國家生技研究園區南側大門

捷運

至「南港站」2 號出口右轉轉乘公車：212(直)、212(區)、270 或 藍 25 (* 至圓拱橋站下車) 至「南港展覽館站」5 號出口對面轉乘公車：212、276、306、620、645、679、205、小 5、小 1、小 12 (* 至圓拱橋站) 至「圓拱橋站」下車後，轉入研究院路二段 12 巷，步行約 400 公尺即為國家生技研究園區南側大門

自行開車

車輛請一律駛入園區地下停車場，平面道路不開放，除申請放行車輛外，其餘車輛請勿行駛平面



SHUTTLE BUS SERVICE

— 接駁車等候處 —

國家生技研究園區巡迴接駁專車時刻表

- ◆ 巡迴接駁專車行駛路線如下表所示 (110 年 2 月 1 日開始行駛)
- ◆ 專車車號：KKA-0266 (備援車輛 KKA-0262)
- ◆ 行駛班次：專車司機會以紅色字體標示的時間準時發車，中間站停靠時間僅供參考 (因會受路況等因素影響)，建議欲搭乘者提前 5~10 分鐘至停靠站點等車

停 靠 站	生技園區		中研院		生技園區		捷運南港展覽館站		食藥署 2	捷運南港站		生技園區
	AC棟	F棟	活動 中心	萊爾富 超商前	AC棟	F棟	經貿 二路站	2 號口 (對面)		1 號口 (旁邊)	AC棟	
時間	09:00	09:00	09:05	09:07	09:10	09:10	09:13	09:19	09:25	09:30		09:35
時間	09:45	09:45	09:50	09:52	09:55	09:55	09:58	10:04	10:10	10:15		10:20
時間	10:30	10:30	10:35	10:37	10:40	10:40	10:43	10:49	10:55	11:00		11:05
時間	11:15	11:15	11:20	11:22	11:25	11:25	11:28	11:34	11:40	11:45		11:50
時間	12:05	12:05	12:10	12:12	12:15	12:15	12:18	12:24	12:30	12:35		12:40
時間	13:10	13:10	13:15	13:17	13:20	13:20	13:23	13:29	13:45	13:45		13:50
時間	14:00	14:00	14:05	14:07	14:10	14:10	14:13	14:19	14:30	14:35		14:40
時間	14:50	14:50	14:55	14:57	15:00	15:00	15:03	15:09	15:20	15:25		15:30
時間	15:40	15:40	15:45	15:47	15:50	15:50	15:53	15:59	16:10	16:15		16:20
時間	16:30	16:30	16:35	16:37	16:40	16:40	16:43	16:49	17:00	17:05		17:10

[illegible]

***Save the Date
for 2027***



BIO Asia-Taiwan

Jul. 28 - Aug. 1, 2027

International Conference & Exhibition

Taipei, Taiwan



www.bioasiataiwan.com

2026 NBRP DEMO & PITCH DAY

*Science to Impact,
Powered by Innovation and Resources*



主辦單位 /



共同主辦單位 /



生物技術開發中心
Development Center for Biotechnology

協辦單位 /



NIBR 國家實驗研究院
國家生物模式中心
National Center for Biomodels



贊助單位 /



pwc 資誠

